Bayi

Bayi Biopharma is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative immuno-oncology therapies. The company focuses on targeting the tumor microenvironment and immune checkpoints to treat various cancers. Its lead candidate, BY101, is a humanized monoclonal antibody targeting CD47, designed to enhance the phagocytic activity of macrophages against tumor cells while minimizing hematological side effects. Bayi Biopharma is also advancing a pipeline of next-generation biologics, including bispecific antibodies and fusion proteins like BY102, which targets both PD-L1 and TGF-beta. The company's research is supported by a proprietary platform for antibody engineering and tumor microenvironment modulation. Bayi Biopharma aims to address unmet medical needs in patients with refractory or metastatic solid tumors and hematologic malignancies.